| Indicators | Browse All

Eikon Therapeutics, Inc. (EIKN)

Healthcare | Biotechnology | Millbrae, United States | NasdaqGS
10.34 USD -0.10 (-0.958%) ⇩ (July 14, 2026, 9:36 a.m. EDT)

Short-term:★★⯪☆☆Long-term:★★⯪☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 6:41 a.m. EDT

The immediate outlook is neutral despite a recent bounce; the stock has recovered from a low of $7.90 to trade near $10.60, yet it remains significantly below its $17.40 high and trades under its 200-day average, suggesting the broader trend is still downward. The recent price action shows volatility with a spike to $13.05 followed by a pullback, indicating indecision rather than a confirmed breakout. Fundamentally, the company is a biotech firm with no earnings, negative forward P/E, and significant operating cash outflows, which precludes any long-term buy rating. While the balance sheet is fortified with substantial cash relative to debt and a high current ratio, the lack of profitability and the speculative nature of the sector keep the long-term assessment neutral. There is absolutely no dividend income to consider, making this a pure capital appreciation play with high risk.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.101336
AutoETS0.101798
AutoARIMA0.102505
AutoTheta0.194365

Forecast horizon: 60 days | Selected: MSTL

Forecast Reliability
Score 34%
H-stat 1.63
Ljung-Box p 0.000
Jarque-Bera p 0.473
Excess Kurtosis -0.62
Attribute Value
Sector Healthcare
Debt to Equity Ratio 46.276
Market Cap 559,793,408
Forward P/E -1.67
Website https://eikontx.com

Info Dump

Attribute Value
52 Week Change -0.30400002
Address1 230 Harriet Tubman Way
All Time High 17.4
All Time Low 7.9
Ask 13.38
Ask Size 2
Average Daily Volume10 Day 440,160
Average Daily Volume3 Month 358,414
Average Volume 358,414
Average Volume10Days 440,160
Bid 7.49
Bid Size 2
Book Value 10.172
City Millbrae
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 10.34
Current Ratio 11.75
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 10.52
Day Low 10.0448
Debt To Equity 46.276
Display Name Eikon Therapeutics
Earnings Timestamp 1,778,529,600
Earnings Timestamp End 1,778,529,600
Earnings Timestamp Start 1,778,529,600
Ebitda -310,081,984
Ebitda Margins 0.0
Enterprise To Ebitda -0.993
Enterprise Value 307,856,288
Eps Current Year -6.34883
Eps Forward -6.18528
Eps Trailing Twelve Months -6.32
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 10.4522
Fifty Day Average Change -0.11219978
Fifty Day Average Change Percent -0.010734562
Fifty Two Week Change Percent -30.400002
Fifty Two Week High 17.4
Fifty Two Week High Change -7.0599995
Fifty Two Week High Change Percent -0.40574712
Fifty Two Week Low 7.9
Fifty Two Week Low Change 2.44
Fifty Two Week Low Change Percent 0.30886075
Fifty Two Week Range 7.9 - 17.4
Financial Currency USD
First Trade Date Milliseconds 1,770,301,800,000
Float Shares 29,843,377
Forward Eps -6.18528
Forward P E -1.671711
Full Exchange Name NasdaqGS
Full Time Employees 384
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.17385
Held Percent Institutions 0.64515996
Implied Shares Outstanding 54,138,628
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,026-02-05
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Long Name Eikon Therapeutics, Inc.
Market us_market
Market Cap 559,793,408
Market State REGULAR
Max Age 86,400
Message Board Id finmb_638227772
Most Recent Quarter 1,774,915,200
Net Income To Common -342,059,008
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 565,748,662
Number Of Analyst Opinions 5
Open 10.41
Operating Cashflow -223,796,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 341 777 0566
Previous Close 10.44
Price Eps Current Year -1.6286465
Price Hint 2
Price To Book 1.016516
Profit Margins 0.0
Quick Ratio 11.366
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.09999943
Regular Market Change Percent -0.95784897
Regular Market Day High 10.52
Regular Market Day Low 10.0448
Regular Market Day Range 10.0448 - 10.52
Regular Market Open 10.41
Regular Market Previous Close 10.44
Regular Market Price 10.34
Regular Market Time 1,784,036,164
Regular Market Volume 20,337
Sand P52 Week Change 0.20365608
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 54,138,628
Shares Percent Shares Out 0.0855
Shares Short 4,631,532
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 4,065,276
Short Name Eikon Therapeutics, Inc.
Short Percent Of Float 0.1137
Short Ratio 11.42
Source Interval 15
State CA
Symbol EIKN
Target High Price 32.0
Target Low Price 5.0
Target Mean Price 24.8
Target Median Price 29.0
Total Cash 512,182,016
Total Cash Per Share 9.461
Total Debt 254,831,008
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -6.32
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 11.410833
Two Hundred Day Average Change -1.0708332
Two Hundred Day Average Change Percent -0.09384356
Type Disp Equity
Volume 20,337
Website https://eikontx.com
Zip 94,030